1[1]Demertris AJ,Todo S,Van Thiel DH et al.Evolution of hepatitis B virusliver disease after hepatic replacement.Am J Pathol,1990,137:667
2[2]Lam PWY,Wachs M,Somberg KA et al.Fibrosing cholestatic hepatitis in renal transplant recipients.Transplantation,1996,61: 378
3[3]Harrison RF,Davies MH,Goldin RD et al.Recurrent hepatitis B in liver allografts: a distinctive form rapidly developing cirrhosis.Histopathology,1993,23:21
4[4]Lau JYN,Bain VG,Davies SE et al.High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis.Gastroenterology,1992,102:956
5[5]Mason AL,Wick M,White HM et al.Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis.Gastroenterology,1993,105: 237
6[6]Jamal H,Regenstein F,Farr G et al.Prolonged survival in FCH with long term ganciclovir therapy.Am J Gastroenterol,1995 (5): 1027
7[7]Fairley CK,Mijch A,Gust ID et al.The increased risk of fatal liver disease in renal transplant patients who are HBeAg and/or HBVDNA positive.Transplantation,1991,52:497
8[8]Lukas KK,Thomas G,Charles RPG.Fatal hepatitis B virus infection with fibrosing cholestatic hepatitis following renal transplantation.Nephrol Dial Transplant,1998,13:1571
9[9]Lau JYN,Bain VG,Smith HM et al.Modulation of hepatitis B viral antigen expression by immnnosuppressive drugs in primary hepatocyte culture.Transplantation,1992,53: 894
10[10]Wong PY,Marinos G,Peakman M et al.FK506 in liver transplantation for chronic hepatitis B:in vitro studies on lymphocyte activation and virus replication.Liver Transpl Surg,1995,1(6) :362
